NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Alvotech (ALVO) Stock Analysis

Alvotech (ALVO) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALVO

$5.13

+$0.01 (+0.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALVO with… →

ALVO Key Statistics

As of Oct 21, 2026
Trading
Open
$5.14
Previous Close
$5.12
Day's Range
5.12–5.24
52-Week Range
2.94–8.50
Volume
480.52K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.21
Valuation
Market Cap
$1.83B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.29
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.70
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$586.32M+19.74%
Net Income (FY)
$27.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
−36.31%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
356.82M
1-Year Return
−39.79%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
1.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALVO closed at $5.13, −39.79% over 1 year.

Alvotech (ALVO) has a market capitalization of $1.83B.

In fiscal 2025, ALVO reported revenue of $586.32M.

ALVO Stock Return by Calendar Year

Alvotech (ALVO) return since Jun 2022: what $10,000 became

1 year
$10,000 $6,021
−39.79%
3 years
$10,000 $5,910
−40.90%
Since Jun 2022
$10,000 $4,584
−54.16%

If you had invested $10,000 in Alvotech (ALVO) at the close on June 16, 2022, the earliest close on record here, it would have been worth $4,584 at the close on October 21, 2026: −54.16% in total, −16.42% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025−61.22%
2024+15.24%
2023+14.80%
2022 (partial year)−10.63%

As of October 21, 2026.

ALVO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$586.32M$27.92M4.8%
2024$489.68M−$231.86M−47.3%
2023$91.43M−$551.73M−603.4%
2022$83.03M−$513.58M−618.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$586.32M$350.76M$78.21M$27.92M4.8%
2024$489.68M$304.37M$69.64M−$231.86M−47.3%
2023$91.43M−$69.42M−$354.86M−$551.73M−603.4%
2022$83.03M$18.93M−$346.44M−$513.58M−618.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALVO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricALVODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio3.702.1076% above
Profit margin−36.31%−8.14%28.2 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alvotech (ALVO) is capitalised at $1.83B on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 1,279 employees.

The most recent close on file for ALVO is $5.13, dated October 21, 2026. That is +$0.01 (+0.20%) against the previous close. Over the past 52 weeks the price has ranged from $2.94 to $8.50. The latest close sits 74.49% above that 52-week low.

Financial Health

In fiscal 2025, Alvotech reported revenue of $586.32M. Against the prior fiscal year total of $489.68M, that is a change of +19.74%. The same year closed with net income of $27.92M. Profit margin runs at −36.31%. That is 28.2 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.62.

Across the 4 fiscal years on file, revenue moves from $83.03M in 2022 to $586.32M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 22.29. Measured against sales, the shares trade at 3.7 times revenue. On price-to-sales that is 76.24% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.21. Daily returns over the trailing 4 years annualize to a volatility of 58.53%. Over the trailing twelve months the total return is −39.79%. Measured over 3 years, that is −16.08% a year compounded.

Growth & Income

The record shows no dividend for ALVO.

The strongest complete calendar year on file is 2024 at +15.24%; the weakest is 2025 at −61.22%. Of the 3 complete calendar years on file, 2 finished higher. So far in 2026 the total return is 0.00%.

Peer Comparison

Alvotech (ALVO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alvotech ALVO $1.83B —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Alvotech has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Visit website →